On March 18, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, reported its abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, being held April 17–22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast
Poster Number: 3179
Poster Board Number: 14
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
Date and Time: Monday, April 20, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 19
The poster presented at the conference will be available for review on the Posters & Publications page on the Company’s website on April 20, 2026 after 5:00 PM PT.
Parties interested in meeting with the Akari team at the conference can direct inquires to [email protected].
For more information about the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, please visit aacr.org.
(Press release, Akari Therapeutics, MAR 18, 2026, View Source [SID1234663693])